Table 2.

Nuclear translocation of NFAT-2 in human keratocytes

Treatment	NFAT-2
	% cells showing nuclear positivity	Number of cells counted
Medium control*	9.3	150
DMSO control†	10.0	150
TPA/ionomycin 2h‡	11.3	150
TPA/ionomycin 4h‡	90.7***	150
CsA§ 1μM then TPA/ionomycin 4h	92.7	150
Tacrolimus∥ 1μM then TPA/ionomycin 4h	55.3‡‡	150
TPA/ionomycin 18h‡	88.0***	150
TPA 2h¶	10.0	150
TPA 4 h¶	64.7¶¶	150
CsA§ 1μM then TPA (4h)	60.7	150
Tacrolimus∥ 1μM then TPA (4h)	16.0‡‡‡	150
TPA 18h¶	95.3¶¶	150
Increased extracellular calcium 2h**	10.0	150
Increased extracellular calcium 4h**	86.7¶¶¶	150
CsA§ 1μM then increased extracellular calcium 4h	43.3§§	150
Tacrolimus∥ 1μM then increased extracellular calcium 4h	12.7§§	150
Increased extracellular calcium 18h**	89.3¶¶¶	150

^*Low calcium (70 μM) medium,

^†Vehicle control,

^‡TPA (50 nM) plus ionomycin (1 μM),

^§Pre-treatment with CsA for 1 h,

^¶TPA (50 nM),

^∥Pre-treatment with tacrolimus for 1 h,

^**Raised extracellular calcium (1.5 mM),

^***P<0.0001 compared to DMSO control,

^¶¶P<0.0001 compared to DMSO control,

^¶¶¶P<0.0001 compared to medium control,

^§§P<0.0001 compared to increased extracellular calcium 4 h,

^‡‡‡P<0.0001 compared to TPA 4 h,

^‡‡P<0.0001 compared to TPA plus ionomycin 4 h.